亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonists

彭布罗利珠单抗 不利影响 医学 临床试验 肿瘤科 内科学 免疫疗法 佐剂 免疫学 免疫系统 安慰剂 癌症 癌症免疫疗法 黑色素瘤 Toll样受体9 头颈部癌 乙肝疫苗 接种疫苗 CpG寡核苷酸 易普利姆玛 药理学 乙型肝炎 癌症疫苗 肝炎
作者
Robert S. Janssen,Robert L. Coffman
出处
期刊:Vaccine [Elsevier BV]
卷期号:79: 128437-128437
标识
DOI:10.1016/j.vaccine.2026.128437
摘要

There is a concern that stimulating the innate immune system with vaccine adjuvants could, hypothetically, lead to autoimmunity; however, evidence is lacking to support these concerns. We review and evaluate immune-mediated adverse events from three sets of clinical studies using toll-like receptor 9 (TLR9) agonists (CpG-ODN) as vaccine adjuvants and therapeutic agents in patients with cancer: 1) a comparison of immune-mediated adverse events across phase 1-3 clinical trials of the hepatitis B vaccine HEPLISAV-B (HepB-CpG) with the alum-adjuvanted hepatitis B vaccine (HepB-alum); 2) an analysis of the rates of immune-mediated adverse events across clinical trials of COVID-19 vaccines using the CpG 1018 adjuvant; and 3) the rates of immune-mediated conditions in a study of the CpG-ODN nelitolimod (SD-101) combined with the immune checkpoint inhibitor pembrolizumab in patients with advanced melanoma or head and neck cancer, compared with rates in historical studies of pembrolizumab monotherapy. In the current analysis, the rate of potential immune-mediated adverse events was similar for HepB-CpG (0.32%) and HepB-alum (0.38%). Few adverse events of special interest (including immune-mediated events) were observed with any of the CpG 1018-adjuvanted COVID-19 vaccines (0-2.1% across studies), and rates were similar to placebo (0.6-3.3%). The rate of immune-mediated events for patients who received nelitolimod and pembrolizumab was 21.8% versus 19.8% for those who received pembrolizumab alone. No increased risk of potential immune-mediated adverse events was observed with HepB-CpG or CpG 1018-adjuvanted COVID-19 vaccines. In patients with cancer treated with programmed cell death protein 1 blockade, repeated treatment with nelitolimod did not increase the frequency of such events. Data evaluated in this review show no increased risk for potential autoimmune disorders with HepB-CpG or CpG 1018-adjuvanted COVID-19 vaccines. Combining CpG-ODN with a checkpoint inhibitor did not increase the rate of immune-mediated conditions.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
超级的迎梅完成签到,获得积分10
9秒前
机智的白卉的应助被u680513采纳,获得10
11秒前
科研通AI6.3的应助被u680513采纳,获得10
15秒前
小蘑菇的应助被吴彦祖采纳,获得10
19秒前
23秒前
科研通AI6.4的应助被u855744采纳,获得10
29秒前
科研通AI6.3的应助被u855744采纳,获得10
31秒前
科研通AI6.3的应助被u264877采纳,获得10
31秒前
科研通AI6.2的应助被u855744采纳,获得10
33秒前
科研通AI6.3的应助被u855744采纳,获得10
33秒前
科研通AI6.2的应助被u264877采纳,获得10
36秒前
科研通AI6.3的应助被u264877采纳,获得10
37秒前
风吹麦浪的应助被u583484采纳,获得10
37秒前
科研通AI6.3的应助被u264877采纳,获得10
41秒前
漂亮的新梅完成签到,获得积分10
51秒前
七七完成签到 ,获得积分10
58秒前
忧郁的数据线关注了科研通微信公众号
1分钟前
1分钟前
syvshc的应助被u721406采纳,获得10
1分钟前
u588294驳回了852的应助
1分钟前
1分钟前
1分钟前
遇上就这样吧给u266829的求助进行了留言
1分钟前
顺利手链完成签到,获得积分10
1分钟前
生动的昊焱完成签到,获得积分10
1分钟前
阿切尔代的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
吴彦祖发布了新的文献求助10
1分钟前
大胆醉卉完成签到,获得积分10
1分钟前
吴彦祖完成签到,获得积分10
1分钟前
识时务这也完成签到,获得积分10
1分钟前
烂漫琳完成签到,获得积分10
1分钟前
张哩哩完成签到,获得积分10
2分钟前
2分钟前
Jason完成签到,获得积分10
2分钟前
2分钟前
Jason发布了新的文献求助10
2分钟前
今后的应助被生锈的铁片采纳,获得10
2分钟前
务实寒烟完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185144
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834129
捐赠科研通 7782640
什么是DOI,文献DOI怎么找? 3434531
关于科研通互助平台的介绍 2558762
邀请新用户注册赠送积分活动 2481206